AI Terminal
Elanix Biotechnologies AG
M&A Activity • May 23, 2018
136_rns_2018-05-23_ec2bcc94-e7dd-40f8-94c3-b2a333b100d2.html
M&A Activity
Open in ViewerOpens in native device viewer
News Details
Corporate | 23 May 2018 08:00
Elanix Biotechnologies AG: Elanix Biotechnologies AG strengthens its sales network by signing an Agreement with MedBioSante, Moscow-Based Distributor for GYNrepair(R)
DGAP-News: Elanix Biotechnologies AG / Key word(s): Contract/Agreement
23.05.2018 / 08:00
The issuer is solely responsible for the content of this announcement.
PRESS RELEASE
Elanix Biotechnologies AG strengthens its sales network by signing an Agreement with MedBioSante, Moscow-Based Distributor for GYNrepair(R)
Collaboration with MedBioSante Extends Sales of Advanced Skin Care Products to Russian Market
Berlin, Germany, 23 May, 2018 — Elanix Biotechnologies AG (FRA: ELN), a developer of tissue regeneration products for chronic and acute wound care and advanced skin care products for dermatological and gynaecological applications, has signed a distribution agreement with MedBioSante to make its progenitor cell-based creams available in Russia. Through this partnership, Elanix will initially sell its products via a gynaecologist prescription network in Moscow before extending its reach through digital sales channels to other Russian cities and the CIS states from next year.
GYNrepair(R) cream, which is developed and marketed by Elanix’s wholly-owned subsidiary Repair A, contains a proprietary Cell Free Protein Complex (CFPC(R)), including various proteins, such as collagen and fibronectin, and is perfume-free. It is specifically designed for use on the genital external mucosa to soothe the feeling of discomfort, twinges and dryness.
“This collaboration with a Moscow-based specialist distributor is a part of our strategy to increase availability of our advanced skin care products across Europe,” said Tomas Svoboda, CEO of Elanix Biotechnologies. “We look forward to making our GYNrepair cream more widely available as we expand on this partnership and extend our reach across Russia and the CIS states.”
“We are enthusiastic about this new partnership with Elanix Biotechnologies and proud to bring a technology-driven product in the field of gynaecological cosmetics to the Russian market to help meet increasing demand,” said Maia Karlovna Filippova-Kokeladze, CEO of MedBioSante. “We are confident this will represent a long-term partnership and greater collaboration in the future.”
####
Elanix develops and commercializes tissue regeneration products for chronic and acute wound care as well as advanced skin care for dermatological and gynecological applications. Additionally, Elanix provides services in cell therapy and related technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells.
Elanix has registered headquarters in Berlin, Germany, with offices in Wiesbaden, Germany and Nyon, Switzerland. It is listed in the Regulated Market on the Frankfurt Stock Exchange under the symbol ELN.F. For more information and updates, visit www.elanixbiotechnologies.com .
Follow us on Twitter @elanix_biotech
MedBioSante , headquartered in Moscow (Russia) and with a branch in Geneva (Switzerland), provides outsourcing services throughout Russia, CIS and Eastern European countries for pharmaceutical and cosmetic companies. MedBioSante operates in the area of distribution, sales and the promotion of pharmaceutical products, foodstuffs and cosmetics and provides services in the field of certification and registration of medical devices and pharmaceutical products throughout the Russian Federation, CIS and Eastern European countries.
Contacts:
Elanix Biotechnologies AG
Magdalena Onyszkiewicz
Tel: +41 78 667 3650
Disclaimer / Forward-looking statements:
This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
23.05.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Elanix Biotechnologies AG |
| Kurfürstendamm 32 | |
| 10719 Berlin | |
| Germany | |
| Phone: | +41 22 363 66 40 |
| Fax: | +41 22 363 66 41 |
| E-mail: | [email protected] |
| Internet: | www.elanixbiotechnologies.com |
| ISIN: | DE000A0WMJQ4 |
| WKN: | A0WMJQ |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf |
| End of News | DGAP News Service |